Sugi Predict

Sugi Predict / Targets / LONP1

LONP1

Lon protease homolog, mitochondrial · P36776 · LONP1 on Sugi Atlas →

4,426 patent compounds predicted against LONP1, 2,610 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3143815 SCHEMBL3143815 0.66 18/20
SCHEMBL3143828 SCHEMBL3143828 0.66 18/20
SCHEMBL2787993 SCHEMBL2787993 0.56 18/20
SCHEMBL3164160 SCHEMBL3164160 0.68 17/20
SCHEMBL3139040 SCHEMBL3139040 0.67 17/20
SCHEMBL3139055 SCHEMBL3139055 0.67 17/20
SCHEMBL3169902 SCHEMBL3169902 0.66 17/20
SCHEMBL3629986 SCHEMBL3629986 0.66 17/20
SCHEMBL903414 SCHEMBL903414 0.79 16/20
SCHEMBL2936754 SCHEMBL2936754 0.69 16/20
SCHEMBL464464 SCHEMBL464464 0.64 16/20
SCHEMBL7387795 SCHEMBL7387795 0.55 16/20
SCHEMBL3152441 SCHEMBL3152441 0.95 15/20
SCHEMBL2506640 SCHEMBL2506640 0.91 15/20
SCHEMBL3165922 SCHEMBL3165922 0.87 15/20
SCHEMBL2125847 SCHEMBL2125847 0.63 15/20
SCHEMBL2125581 SCHEMBL2125581 0.59 15/20
SCHEMBL464440 SCHEMBL464440 1.00 14/20
SCHEMBL464428 SCHEMBL464428 0.64 14/20
SCHEMBL1688077 SCHEMBL1688077 0.63 14/20

Clinical trials — most relevant to LONP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings PHASE4COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept PHASE3COMPLETED
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML PHASE3UNKNOWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival PHASE1UNKNOWN
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED
LIPCAR, Cuproptosis, and Α-SMA in the Pathogenesis of AMI and Remodeling nanNOT_YET_RECRUITING
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Reactive Oxygen Species Following Aortic Valve Replacement nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease nanENROLLING_BY_INVITATION
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence nanNOT_YET_RECRUITING
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells nanRECRUITING
Biological Markers in Parkinson's Disease nanCOMPLETED
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis nanUNKNOWN
Mitochondrial Dysfunction in Phelan-McDermid Syndrome nanCOMPLETED
Cardiac Mitochondrial Function in Explanted Human Hearts nanUNKNOWN
The Natural History of Mitochondrial Diseases nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a LONP1 binder may also engage these)

ProteinNameSimilarity
Q8CGK3 — 1.000 Q8CGK3 →
Q59HJ6 — 1.000 Q59HJ6 →
Q924S5 — 1.000 Q924S5 →
P93648 — 0.996 P93648 →
A2YQ56 — 0.996 A2YQ56 →
B8BDV1 — 0.994 B8BDV1 →
A8XFM8 — 0.994 A8XFM8 →
Q2TAF8 — 0.992 Q2TAF8 →
O44952 — 0.992 O44952 →
Q9DBN5 — 0.991 Q9DBN5 →
O64948 — 0.991 O64948 →
Q7KUT2 — 0.991 Q7KUT2 →
Q0J032 — 0.990 Q0J032 →
Q3MIB4 — 0.990 Q3MIB4 →
P93655 — 0.990 P93655 →
Q754Q9 — 0.990 Q754Q9 →
Q5R6M5 — 0.989 Q5R6M5 →
Q8TB37 — 0.989 Q8TB37 →
Q5PQY6 — 0.989 Q5PQY6 →
Q3SX23 — 0.989 Q3SX23 →
Q00WL5 — 0.989 Q00WL5 →
Q86WA8 — 0.989 Q86WA8 →
A0L516 — 0.988 A0L516 →
Q9CQN1 — 0.988 Q9CQN1 →
Q69UZ3 — 0.988 Q69UZ3 →
P93647 — 0.988 P93647 →
Q5H432 — 0.987 Q5H432 →
Q32JJ5 — 0.987 Q32JJ5 →
Q1IPZ8 — 0.987 Q1IPZ8 →
Q5RAZ4 — 0.987 Q5RAZ4 →